Fig 4.
Dose-intensity. (A) Arm A (bevacizumab); (B) arm B (bevacizumab plus temsirolimus); (C) arm C (bevacizumab plus sorafenib); (D) arm D (sorafenib plus temsirolimus). Bevacizumab is shown in blue, temsirolumus in gold, and sorafenib in gray.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.